A market expanding faster than most analysts predicted
Estimates vary depending on which research firm you ask, but the direction is consistent. One widely cited projection puts the global traditional Chinese medicine market at 282.36 billion dollars in 2026, expected to rise to 513.6 billion dollars by 2035, growing at nearly 7 percent annually. Other analysts land on more conservative figures, but almost every forecast agrees the trajectory points sharply upward.
What is driving the number is not mysterious. Chinese herbal medicine accounts for close to half of total market share, with acupuncture, cupping, and tui na making up most of the rest. Consumers are not just curious anymore. Roughly three quarters of consumers now say they prefer herbal-based wellness products for preventive healthcare, while about two thirds use TCM therapies specifically for managing chronic conditions.
The World Health Organization just gave it a major institutional push
For decades, traditional medicine sat on the margins of global health policy discussions. That changed in a meaningful way in 2025. During the 78th World Health Assembly in Geneva, delegates emphasized research, innovation, regulation, equity and collaboration, and on 26 May 2025 Member States agreed on the new WHO Global Traditional Medicine Strategy 2025 to 2034.
The strategy is not symbolic. It sets guiding principles and four objectives: strengthen evidence, ensure safety and regulation, integrate traditional, complementary and integrative medicine into health systems, and optimize its cross-sectoral value. A follow-up global summit is already scheduled, since in December 2025 the second WHO Global Summit on Traditional Medicine will convene global leaders under the theme of restoring balance. That kind of sustained institutional attention rarely happens by accident.
China is backing its own tradition with real policy muscle
None of this growth would mean much without domestic support, and China has been unusually deliberate about it. Government backing, evidenced by China’s insurance catalog now listing 3,900 drugs, has broadened access and accelerated producer revenues. That is not a small administrative tweak. It changes what ordinary patients can afford and, by extension, what doctors are willing to prescribe.
Regulators are also pushing manufacturers toward more rigorous science rather than relying purely on tradition. Intensifying research and development, highlighted by 12 approvals from China’s drug regulator in 2024, three of them Class 1 innovative formulations, signals a pipeline shift toward evidence-based formulations. On the export side, China’s push to set 180 domestic and 30 international standards by 2026 anchors export credibility, which matters enormously if TCM products are ever going to clear customs and pharmacy shelves in skeptical markets.
The clinical evidence base is finally catching up
Skepticism toward TCM outside China has often centered on a lack of rigorous trials. That gap is closing, slowly but steadily. High-quality randomized trials covering chronic pain, post-operative recovery, and mental health have intensified trust among clinicians and regulators, which is a meaningful departure from the anecdote-heavy reputation the field once carried.
This growing evidence base is also reshaping how practitioners are trained and supervised. Institutional demand has stimulated guideline development, aligning dosage, technique, and safety metrics with Western protocols. In plain terms, acupuncture and herbal dosing are increasingly being measured and standardized the same way a conventional drug trial would be, rather than left to individual practitioner judgment alone.
Acupuncture has quietly become mainstream in Western healthcare
Few TCM practices illustrate the shift better than acupuncture. What was once considered fringe is now something many patients have simply tried. Nearly 10 percent of adults in the United States have already experienced acupuncture, and roughly 60 percent say they would opt for treatment if it were covered by insurance. That gap between interest and access is exactly where insurers and policymakers are now stepping in.
Europe tells a similar story. Comparable momentum in the United Kingdom, Austria, and other European Union states has embedded acupuncture services inside national health structures, reinforcing recurring revenue channels. It is worth noting this did not happen through marketing campaigns. It happened because pain clinics and physical therapists started referring patients who had run out of other options.
Hospitals and insurers are making structural room for it
Integration is the word that keeps surfacing in industry reports, and it describes something concrete. Roughly 43 percent of healthcare facilities have expanded integrative wellness programs that combine TCM therapies with conventional rehabilitation and preventive healthcare services. That is a meaningful share of institutions choosing to formally house both systems under one roof rather than treating them as competitors.
Insurance reimbursement is following a similar arc outside China as well. South Korea has pursued a parallel inclusion strategy for TCM-adjacent formulations in its national coverage, reflecting a broader regional pattern of governments treating cost-effective chronic disease management as a public health priority rather than a private wellness choice. When insurers start paying, adoption tends to follow.
Herbal medicine is meeting modern pharmaceutical science halfway
The herbal side of TCM has undergone its own quiet transformation. Rather than staying purely traditional, manufacturers are applying laboratory-grade standardization to plant-based formulas. The application of modern biotechnology in TCM drug development is improving product standardization and enhancing therapeutic potential, which addresses one of the oldest criticisms of herbal medicine: inconsistent potency from batch to batch.
Academic collaboration is reinforcing this shift. Global universities are collaborating with Chinese medical institutions to explore the integration of traditional practices with Western medicine. Meanwhile, digital health platforms are leveraging AI and big data analytics to personalize TCM treatments, making them more evidence-based, a development that would have sounded almost contradictory a generation ago.
A widening global network of standards, farms, and training
Supply chains and education systems around TCM have grown considerably more organized. India’s National Medicinal Plants Board finances cultivation over 56,305 hectares, nurturing a robust raw-material pipeline and augmenting bilateral trade corridors, which shows the ecosystem now extends well beyond China’s own borders. Neighboring markets are innovating too, since Japan and South Korea are refining computerized herbal dispensing robots, reinforcing clinical safety.
Regional regulators are also adjusting their frameworks rather than ignoring the trend. Australian regulators are streamlining listing pathways, making the Asia-Pacific region a cohesive ecosystem of supply, demand, and innovation. It is a slow, unglamorous kind of infrastructure building, but it is exactly the kind of groundwork that turns a niche practice into a durable global industry.
The growing pains are real and worth acknowledging
None of this progress erases the field’s genuine limitations. Regulatory fragmentation remains a serious obstacle to broader trust. Fewer than 30 countries globally had fully integrated TCM into their national medical regulatory frameworks by 2023, according to WHO regulatory assessments, which restricts how far certified practitioners can actually work once they leave China.
Quality control concerns have not disappeared either. Concerns over heavy metal contamination and pesticide residues in herbal medicines raise safety issues, leading to import restrictions in some cases. These are not minor footnotes. They are the exact issues that will determine whether TCM keeps expanding into cautious Western regulatory systems or stalls at its current level of acceptance.
Where this leaves the field going into 2027
